Global Information
회사소개 | 문의 | 비교리스트

세계의 좌골신경통 치료 시장(2019-2023년)

Global Sciatica Treatment Market 2019-2023

리서치사 TechNavio (Infiniti Research Ltd.)
발행일 2019년 03월 상품 코드 819277
페이지 정보 영문 119 Pages
가격
US $ 2,500 ₩ 3,122,000 PDF by E-mail (Single User License) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 3,000 ₩ 3,746,000 PDF by E-mail (5-user License) help
동일 사업장 내 5명까지 공유하여 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 4,000 ₩ 4,995,000 PDF by E-mail (Enterprise License) help
동일 기업 내 모든 분들이 공유하여 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 5,000 ₩ 6,244,000 PDF by E-mail (Global License) help
동일 기업 내 모든 분들이 공유하여 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다. 또한 해당 라이선스는 보고서 컨텐츠의 15% 이내로 외부용 문서에 인용 게재가 허용됩니다(예:프레스릴리스, 마케팅 자료, 백서 등).


세계의 좌골신경통 치료 시장(2019-2023년) Global Sciatica Treatment Market 2019-2023
발행일 : 2019년 03월 페이지 정보 : 영문 119 Pages

좌골신경통은 일반적인 요통과 자주 혼동됩니다. 좌골신경통은 증상이 치료되지 않은 채로 있으면 허리에 장기적인 통증을 일으킬 가능성이 있습니다. 따라서 다양한 정부기관이나 비정부 조직은 병상에 대한 사람들의 의식을 높이고 진단의 지연을 방지하기 위해 특정 프로그램을 개시하고 있습니다. 예를 들면 미국정형외과학회(AAOS)의 환자 교육 사이트인 Ortholnfo는 미국의 기사, 비디오 및 애니메이션을 통해서 좌골신경통에 대해 인식을 높이고 있습니다. 마찬가지로 다양한 국가가 좌골신경통을 포함한 다양한 건강 관련 문제에 관한 포괄적이고 관련성 있는 건강 정보를 제공합니다. 이러한 의식 향상 프로그램에 의해 환자는 질환 및 이용 가능한 안전한 치료법의 선택사항에 대해 알 수 있으며, 예측기간 중 시장 성장이 촉진될 것으로 예상됩니다. Technavio의 애널리스트는 세계의 좌골신경통 치료 시장이 2023년까지 8%에 근접한 CAGR로 성장할 것으로 예측했습니다.

세계의 좌골신경통 치료(Sciatica Treatment) 시장에 대해 조사 분석했으며, 시장 규모와 성장률, 시장 동향, 시장 성장 촉진요인과 과제, 시장 기회, 주요 벤더 등에 대한 체계적인 정보를 제공합니다.

목차

제1장 주요 요약

제2장 보고서의 범위

  • 서론 1
  • 서론 2
  • 달러의 통화 환율

제3장 시장 상황

  • 시장 생태계
  • 시장 특징
  • 시장 세분화 분석

제4장 시장 규모

  • 시장 정의
  • 시장 규모(2018년)
  • 시장 규모 및 예측(2018-2023년)

제5장 Five Forces 분석

  • 구매자의 협상력
  • 공급업체의 협상력
  • 신규 참여업체의 위협
  • 대체품의 위협
  • 경쟁사의 위협
  • 시장 현황

제6장 파이프라인

제7장 시장 세분화 : 종류별

  • 시장 세분화 : 종류별
  • 종류별 비교 : 시장 규모 및 예측(2018-2023년)
  • 비외과 치료
  • 외과 치료
  • 시장 기회 : 종류별

제8장 고객 상황

제9장 지역 상황

  • 지역별 세분화
  • 지역별 비교 : 시장 규모 및 예측(2018-2023년)
  • 북미
  • 유럽
  • 아시아
  • 기타 지역
  • 주요 국가
  • 시장 기회

제10장 의사결정 체계

제11장 성장 촉진요인과 과제

  • 시장 성장 촉진요인
  • 시장 과제

제12장 시장 동향

제13장 벤더 상황

  • 개요
  • 창조적 파괴 상황
  • 경쟁 시나리오

제14장 벤더 분석

  • 대상 벤더
  • 벤더 분류
  • 벤더의 시장 포지셔닝
  • Bayer AG
  • Johnson & Johnson Services, Inc.
  • Novartis AG
  • Pfizer Inc.
  • Teva Pharmaceutical Industries Ltd.

제15장 부록

  • 조사 방법
  • 약어 리스트

제16장 TechNavio 소개

KSM 19.04.15

About this market

Sciatica is often confused with general back pain. Sciatica can cause long-term pain in the lower back if the condition is left untreated. Hence, various government and non-governmental organizations are initiating certain programs to increase awareness among people about the condition and avoid delay in diagnosis. For instance, Ortholnfo, the patient education site of the American Academy of Orthopaedic Surgeons (AAOS), is providing awareness about sciatica, through articles, videos, and animations, in the US. Similarly, initiative from different countries are providing comprehensive and relevant health information related to various hearth-related problems, including sciatica. Such increasing awareness programs help patients to know about the disease and available safe treatment options, which are expected to drive market growth during the forecast period. Technavio's analysts have predicted that the sciatica treatment market will register a close to 8% by 2023.

Market Overview

Growing prevalence of risk factors for sciatica

Although sciatica occurs more commonly due to spinal cord injuries. It also occurs due to disease conditions such as lumbar spinal stenosis, osteoarthritis, spondylolisthesis, and muscle spasms. Hence, an increase in the number of patients with these diseases may increase the chances of development of sciatica. This, in turn, is expected to aid in the use of available and anticipated treatments and drive the growth of the global sciatica treatment market during the forecast period.

Lack of approved treatments

Most of the patients benefit from this combination of treatment methods such as epidural injections of corticosteroids, physiotherapy, and bracing. However, there is no approved treatment for sciatica. Therefore, the lack of approved treatments for sciatica is expected to hamper the growth of the global sciatica treatment market during the forecast period.

For the detailed list of factors that will drive and challenge the growth of the sciatica treatment market during the 2019-2023, view our report.

Competitive Landscape

The market appears to be highly fragmented and with the presence of several vendors. This market research report will help clients identify new growth opportunities and design unique growth strategies by providing a comprehensive analysis of the market's competitive landscape and offering information on the products offered by companies.

TABLE OF CONTENTS

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

  • 2.1 Preface
  • 2.2 Preface
  • 2.3 Currency conversion rates for US$

PART 03: MARKET LANDSCAPE

  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis

PART 04: MARKET SIZING

  • Market definition
  • Market sizing 2018
  • Market size and forecast 2018-2023

PART 05: FIVE FORCES ANALYSIS

  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

PART 06: PIPELINE

PART 07: MARKET SEGMENTATION BY TYPE

  • Market segmentation by type
  • Comparison by type
  • Non-surgical treatment - Market size and forecast 2018-2023
  • Surgical treatment - Market size and forecast 2018-2023
  • Market opportunity by type

PART 08: CUSTOMER LANDSCAPE

PART 09: GEOGRAPHIC LANDSCAPE

  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2018-2023
  • Europe - Market size and forecast 2018-2023
  • Asia - Market size and forecast 2018-2023
  • ROW - Market size and forecast 2018-2023
  • Key leading countries
  • Market opportunity

PART 10: DECISION FRAMEWORK

PART 11: DRIVERS AND CHALLENGES

  • Market drivers
  • Market challenges

PART 12: MARKET TRENDS

PART 13: VENDOR LANDSCAPE

  • Overview
  • Landscape disruption
  • Competitive scenario

PART 14: VENDOR ANALYSIS

  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • Bayer AG
  • Johnson & Johnson Services, Inc.
  • Novartis AG
  • Pfizer Inc.
  • Teva Pharmaceutical Industries Ltd.

PART 15: APPENDIX

  • Research methodology
  • List of abbreviations

PART 16: EXPLORE TECHNAVIO

List of Exhibits

  • Exhibit 01: Global pharmaceuticals market
  • Exhibit 02: Segments of global pharmaceuticals market
  • Exhibit 03: Market characteristics
  • Exhibit 04: Market segments
  • Exhibit 05: Market definition - Inclusions and exclusions checklist
  • Exhibit 06: Market size 2018
  • Exhibit 07: Global market: Size and forecast 2018-2023 ($ millions)
  • Exhibit 08: Global market: Year-over-year growth 2019-2023 (%)
  • Exhibit 09: Five forces analysis 2018
  • Exhibit 10: Five forces analysis 2023
  • Exhibit 11: Bargaining power of buyers
  • Exhibit 12: Bargaining power of suppliers
  • Exhibit 13: Threat of new entrants
  • Exhibit 14: Threat of substitutes
  • Exhibit 15: Threat of rivalry
  • Exhibit 16: Market condition - Five forces 2018
  • Exhibit 17: Phase III pipeline molecules: Overview
  • Exhibit 18: Type - Market share 2018-2023 (%)
  • Exhibit 19: Comparison by type
  • Exhibit 20: Non-surgical treatment - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 21: Non-surgical treatment - Year-over-year growth 2019-2023 (%)
  • Exhibit 22: Surgical treatment - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 23: Surgical treatment - Year-over-year growth 2019-2023 (%)
  • Exhibit 24: Market opportunity by type
  • Exhibit 25: Customer landscape
  • Exhibit 26: Market share by geography 2018-2023 (%)
  • Exhibit 27: Geographic comparison
  • Exhibit 28: North America - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 29: North America - Year-over-year growth 2019-2023 (%)
  • Exhibit 30: Top 3 countries in North America
  • Exhibit 31: Europe - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 32: Europe - Year-over-year growth 2019-2023 (%)
  • Exhibit 33: Top 3 countries in Europe
  • Exhibit 34: Asia - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 35: Asia - Year-over-year growth 2019-2023 (%)
  • Exhibit 36: Top 3 countries in Asia
  • Exhibit 37: ROW - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 38: ROW - Year-over-year growth 2019-2023 (%)
  • Exhibit 39: Top 3 countries in ROW
  • Exhibit 40: Key leading countries
  • Exhibit 41: Market opportunity
  • Exhibit 42: Impact of drivers and challenges
  • Exhibit 43: Vendor landscape
  • Exhibit 44: Landscape disruption
  • Exhibit 45: Vendors covered
  • Exhibit 46: Vendor classification
  • Exhibit 47: Market positioning of vendors
  • Exhibit 48: Bayer AG - Vendor overview
  • Exhibit 49: Bayer AG - Business segments
  • Exhibit 50: Bayer AG - Organizational developments
  • Exhibit 51: Bayer AG - Geographic focus
  • Exhibit 52: Bayer AG - Segment focus
  • Exhibit 53: Bayer AG - Key offerings
  • Exhibit 54: Bayer AG - Key customers
  • Exhibit 55: Johnson & Johnson Services, Inc. - Vendor overview
  • Exhibit 56: Johnson & Johnson Services, Inc. - Business segments
  • Exhibit 57: Johnson & Johnson Services, Inc. - Organizational developments
  • Exhibit 58: Johnson & Johnson Services, Inc. - Geographic focus
  • Exhibit 59: Johnson & Johnson Services, Inc. - Segment focus
  • Exhibit 60: Johnson & Johnson Services, Inc. - Key offerings
  • Exhibit 61: Johnson & Johnson Services, Inc. - Key customers
  • Exhibit 62: Novartis AG - Vendor overview
  • Exhibit 63: Novartis AG - Business segments
  • Exhibit 64: Novartis AG - Organizational developments
  • Exhibit 65: Novartis AG - Geographic focus
  • Exhibit 66: Novartis AG - Segment focus
  • Exhibit 67: Novartis AG - Key offerings
  • Exhibit 68: Novartis AG - Key customers
  • Exhibit 69: Pfizer Inc. - Vendor overview
  • Exhibit 70: Pfizer Inc. - Business segments
  • Exhibit 71: Pfizer Inc. - Organizational developments
  • Exhibit 72: Pfizer Inc. - Geographic focus
  • Exhibit 73: Pfizer Inc. - Segment focus
  • Exhibit 74: Pfizer Inc. - Key offerings
  • Exhibit 75: Pfizer Inc. - Key customers
  • Exhibit 76: Teva Pharmaceutical Industries Ltd. - Vendor overview
  • Exhibit 77: Teva Pharmaceutical Industries Ltd. - Business segments
  • Exhibit 78: Teva Pharmaceutical Industries Ltd. - Organizational developments
  • Exhibit 79: Teva Pharmaceutical Industries Ltd. - Geographic focus
  • Exhibit 80: Teva Pharmaceutical Industries Ltd. - Segment focus
  • Exhibit 81: Teva Pharmaceutical Industries Ltd. - Key offerings
  • Exhibit 82: Teva Pharmaceutical Industries Ltd. - Key customers
  • Exhibit 83: Validation techniques employed for market sizing
Back to Top
전화 문의
F A Q